Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

50
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
50
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.5K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

52
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
52

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Sphingosine-1-Phosphate Receptor Modulator, FTY720, Improves Diastolic Dysfunction and Partially Reverses Atrial Remodeling in a Tm-E180G Mouse Model Linked to Hypertrophic Cardiomyopathy.

Circulation. Heart failure·2019
Same author

Tropomyosin pseudo-phosphorylation results in dilated cardiomyopathy.

The Journal of biological chemistry·2018
Same author

Early sensitization of myofilaments to Ca2+ prevents genetically linked dilated cardiomyopathy in mice.

Cardiovascular research·2017
Same author

N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy.

American journal of physiology. Heart and circulatory physiology·2015
Same author

Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, TRV120023, in a dilated cardiomyopathy model.

Cardiovascular research·2015
Same author

Ceramide-mediated depression in cardiomyocyte contractility through PKC activation and modulation of myofilament protein phosphorylation.

Basic research in cardiology·2014

Video Experimental Relacionado

Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

La miocardiopatía dilatada: las causas subyacentes

David F Wieczorek1

  • 1Department of Molecular and Cellular Biosciences, University of Cincinnati College of Medicine, 231 Albert Sabin Way.

Medical research archives
|September 2, 2025
PubMed
Resumen
Este resumen es generado por máquina.

La miocardiopatía dilatada, una enfermedad del corazón, se deriva de factores genéticos y no genéticos. La investigación con modelos de ratón ayuda a comprender sus efectos y a desarrollar nuevos tratamientos para esta enfermedad cardíaca común.

Más Videos Relacionados

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K

Área de la Ciencia:

  • Cardiología
  • La genética
  • Biología molecular

Sus antecedentes:

  • Las enfermedades cardiovasculares son una de las principales causas de mortalidad, con cardiomiopatía dilatada que afecta a 5-8 por cada 100.000 personas.
  • La miocardiopatía dilatada se caracteriza por el agrandamiento de las cámaras cardíacas, la reducción de la función sistólica y la insuficiencia cardíaca.
  • Comprender las causas de la miocardiopatía dilatada es crucial para desarrollar tratamientos efectivos.

Objetivo del estudio:

  • Revisar las causas no genéticas y genéticas de la miocardiopatía dilatada.
  • Para explorar mutaciones humanas en modelos de ratón de miocardiopatía dilatada.
  • Para definir las consecuencias morfológicas y fisiológicas de estas mutaciones.

Principales métodos:

  • Revisión de las etiologías no genéticas: virus, cardiotoxicidad, drogas recreativas y quimioterapia.
  • Centrarse en las etiologías genéticas: genes de proteínas citoesqueléticas y sarcoméricas.
  • Análisis de modelos de ratón con mutaciones relevantes para los humanos.

Principales resultados:

  • Las causas no genéticas identificadas incluyen infecciones, toxinas y ciertos medicamentos.
  • Las causas genéticas implican mutaciones en los genes que codifican las proteínas citoesqueléticas y sarcoméricas.
  • Los modelos de ratón revelan los mecanismos de la enfermedad y las consecuencias de mutaciones específicas.

Conclusiones:

  • Los modelos de ratón proporcionan información valiosa sobre la patogénesis de la miocardiopatía dilatada.
  • Comprender los mecanismos de la enfermedad es clave para desarrollar nuevas estrategias terapéuticas.
  • La investigación adicional tiene como objetivo mejorar la prevención y el tratamiento de la miocardiopatía dilatada.